Liminatus PharmaLIMN -6.99%13 3-Year ROIIC % is 1.72 as of Dec. 2025, which is at its 10-year median of 1.72. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,321 Biotechnology companies, Liminatus Pharma ranks better than 54.73% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Liminatus Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1.72%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Liminatus Pharma's 3-Year ROIIC % or its related term are showing as below:
LIMN's 3-Year ROIIC % is ranked better than 54.73% of 1321
companies
in the Biotechnology industry
Industry Median: -4.44
vs LIMN: 1.72
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Liminatus Pharma 3-Year ROIIC % Related Terms
Liminatus Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Liminatus Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIMN vs GNPX, PCSA, ELAB: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Liminatus Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liminatus Pharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Liminatus Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Liminatus Pharma's 3-Year ROIIC % falls into.
Liminatus Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -2.968 (Dec. 2025) - -2.709 (Dec. 2022) )
/
( 1.454 (Dec. 2025) - 16.501 (Dec. 2022) )
=
-0.259
/
-15.047
=
1.72%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Liminatus Pharma (LIMN) has a 3-Year ROIIC % of 1.72 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Liminatus Pharma and its competitors. This is near median its historical median of 1.72. Over the past decade, Liminatus Pharma's 3-Year ROIIC % has ranged from 1.72 to 1.72. According to the industry distribution chart, Liminatus Pharma ranks #598 out of 1321 companies in the Biotechnology industry, placing it in the top 45.3%.
Is Liminatus Pharma's 3-Year ROIIC % too high?
Liminatus Pharma's current 3-Year ROIIC % of 1.72 is near median its 10-year median of 1.72. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 1.72. Based on the distribution chart, Liminatus Pharma ranks #598 out of 1321 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's 3-Year ROIIC % compare to GNPX and PCSA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #598 out of 1321 companies for 3-Year ROIIC %. This puts Liminatus Pharma in the upper half of its industry. Historically, Liminatus Pharma's own 3-Year ROIIC % has ranged from 1.72 to 1.72 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Liminatus Pharma and its competitors. Liminatus Pharma's current 3-Year ROIIC % is 1.72, which is near median its own 10-year median of 1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current 3-Year ROIIC % of 1.72. The current 3-Year ROIIC % is 1.72, which is near median its 10-year median of 1.72. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current 3-Year ROIIC % is 1.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score
Get the complete analysis for LIMN
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIMN has been successfully added to your 
